Trial Profile

Phase 2 study of L-DOS-47 with Pembrolizumab for treatment of non-small cell lung cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs L-DOS 47 (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

16 Apr 2025 New trial record
10 Apr 2025 According to Helix BioPharma media release, plan to enter L-DOS47 with pembrolizumab into a Phase II study this year for the treatment of non-small cell lung cancer.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com